Mitchell Gross
Physician · Providence Southern California
Credentials: · · · ·
History
- 2023–Present
- 1997–1999
Medical Oncology
- 1994–1997
- 1990–1994
Research
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Clinical Cancer Research · 2009 · 184 citations
European Urology · 2012 · 172 citations
A transcriptional corepressor of Stat1 with an essential LXXLL signature motif
Proceedings of the National Academy of Sciences of the United States of America · 2001 · 149 citations
19 papers
- TD
11 papers
6 papers
5 papers
5 papers
4 papers
- GW
4 papers
- OU
4 papers
Grants
- 2016–2018
Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
National Institute of Biomedical Imaging and Bioengineering · R21
PI · $439.3K · University of Southern California
- 2009–2016
Multi-Scale Complex Systems Transdisciplinary Analysis of Response to Therapy (MC
National Cancer Institute · U54
Project lead · $35.6K · University of Southern California
- 2002–2007
Role of PIASy in Androgen Signaling and Prostate Cancer
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $617.8K · Cedars-Sinai Medical Center
Clinical trials
- 2014–2016
Principal investigator · Terminated
University of Southern California
- 2014–2020
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
Principal investigator · Completed · Phase 2
University of Southern California
- 2013–2016
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Principal investigator · Terminated · Phase 2
University of Southern California
- 2010–2017
Principal investigator · Completed · Phase 1, Phase 2
University of Southern California